Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 1
1982 4
1983 1
1984 4
1985 2
1986 1
1987 1
1988 1
1989 2
1990 1
1992 1
1995 3
1996 1
1997 1
1999 2
2000 1
2001 3
2002 1
2004 2
2005 5
2006 3
2007 5
2008 3
2009 5
2010 5
2011 4
2012 6
2013 2
2014 3
2015 2
2016 1
2017 2
2018 1
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model.
Ivasko SM, Anders K, Grunewald L, Launspach M, Klaus A, Schwiebert S, Ruf P, Lindhofer H, Lode HN, Andersch L, Schulte JH, Eggert A, Hundsdoerfer P, Künkele A, Zirngibl F. Ivasko SM, et al. Among authors: lindhofer h. Front Immunol. 2023 Jan 9;13:1023206. doi: 10.3389/fimmu.2022.1023206. eCollection 2022. Front Immunol. 2023. PMID: 36700232 Free PMC article.
GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F, Ivasko SM, Grunewald L, Klaus A, Schwiebert S, Ruf P, Lindhofer H, Astrahantseff K, Andersch L, Schulte JH, Lode HN, Eggert A, Anders K, Hundsdoerfer P, Künkele A. Zirngibl F, et al. Among authors: lindhofer h. J Immunother Cancer. 2021 Jul;9(7):e002923. doi: 10.1136/jitc-2021-002923. J Immunother Cancer. 2021. PMID: 34285106 Free PMC article.
Immunotherapy of malignant ascites with trifunctional antibodies.
Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H. Heiss MM, et al. Among authors: lindhofer h. Int J Cancer. 2005 Nov 10;117(3):435-43. doi: 10.1002/ijc.21165. Int J Cancer. 2005. PMID: 15906359 Free article.
First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity.
Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H. Ruf P, et al. Among authors: lindhofer h. Cancer Immunol Immunother. 2021 Sep;70(9):2727-2735. doi: 10.1007/s00262-021-02930-7. Epub 2021 Apr 10. Cancer Immunol Immunother. 2021. PMID: 33837852 Free PMC article.
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Knödler M, Körfer J, Kunzmann V, Trojan J, Daum S, Schenk M, Kullmann F, Schroll S, Behringer D, Stahl M, Al-Batran SE, Hacker U, Ibach S, Lindhofer H, Lordick F. Knödler M, et al. Among authors: lindhofer h. Br J Cancer. 2018 Aug;119(3):296-302. doi: 10.1038/s41416-018-0150-6. Epub 2018 Jul 10. Br J Cancer. 2018. PMID: 29988111 Free PMC article. Clinical Trial.
79 results